The current standard treatment for tuberculosis (TB) consists of a combination of four antibiotics administered for 6 to 12 months. There is hence a clear need for new strategies both for shorter treatment periods and that may address the emergence of multi- and extensive drug-resistant TB. Researchers from Scripps Research Institute have reported on the synthesis and preclinical characterization of a series of novel aryl fluorosulfate derivatives designed to be used for the treatment of TB.